Compare AEG & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEG | MEDP |
|---|---|---|
| Founded | 1983 | 1992 |
| Country | Netherlands | United States |
| Employees | 15304 | N/A |
| Industry | Life Insurance | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 13.0B |
| IPO Year | N/A | 2016 |
| Metric | AEG | MEDP |
|---|---|---|
| Price | $8.45 | $459.63 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $473.17 |
| AVG Volume (30 Days) | ★ 4.5M | 247.2K |
| Earning Date | 02-09-2023 | 04-22-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ 20.98 |
| EPS | N/A | ★ 4.28 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $13.19 |
| Revenue Next Year | N/A | $7.75 |
| P/E Ratio | ★ $7.91 | $106.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.71 | $301.90 |
| 52 Week High | $8.81 | $628.92 |
| Indicator | AEG | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 52.33 | 54.03 |
| Support Level | $8.17 | $442.83 |
| Resistance Level | $8.81 | $483.30 |
| Average True Range (ATR) | 0.11 | 14.53 |
| MACD | -0.00 | 0.77 |
| Stochastic Oscillator | 55.78 | 53.14 |
Aegon is a life insurance and long-term savings business listed in the Netherlands. It was listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. In recent years, Aegon has been moving through an extensive transformation program during which management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the company that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile earnings products and recycle capital into capital-light and more predictable strategic businesses.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.